These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 22882654)
1. Use and misuse of multivariable approaches in interventional cardiology studies on drug-eluting stents: a systematic review. D'Ascenzo F; Cavallero E; Biondi-Zoccai G; Moretti C; Omedè P; Bollati M; Castagno D; Modena MG; Gaita F; Sheiban I J Interv Cardiol; 2012 Dec; 25(6):611-21. PubMed ID: 22882654 [TBL] [Abstract][Full Text] [Related]
2. A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population. Zhao YJ; Teng M; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Loh JP; Chan MY Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29316284 [TBL] [Abstract][Full Text] [Related]
3. Are propensity scores really superior to standard multivariable analysis? Biondi-Zoccai G; Romagnoli E; Agostoni P; Capodanno D; Castagno D; D'Ascenzo F; Sangiorgi G; Modena MG Contemp Clin Trials; 2011 Sep; 32(5):731-40. PubMed ID: 21616172 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: A real-world analysis of 11,181 patients from the british columbia cardiac registry. Iqbal MB; Nadra IJ; Ding L; Fung A; Aymong E; Chan AW; Hodge S; Robinson SD; Siega AD; Catheter Cardiovasc Interv; 2016 Jul; 88(1):24-35. PubMed ID: 26945680 [TBL] [Abstract][Full Text] [Related]
5. Time dependent effect on mortality of drug-eluting stents versus bare metal stents. Mølstad P Scand Cardiovasc J; 2012 Aug; 46(4):226-32. PubMed ID: 22462392 [TBL] [Abstract][Full Text] [Related]
6. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions). Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802 [TBL] [Abstract][Full Text] [Related]
7. Survival benefit with drug-eluting stents in observational studies: fact or artifact? Venkitachalam L; Lei Y; Magnuson EA; Chan PS; Stolker JM; Kennedy KF; Kleiman NS; Cohen DJ; Circ Cardiovasc Qual Outcomes; 2011 Nov; 4(6):587-94. PubMed ID: 21988921 [TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease. Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052 [TBL] [Abstract][Full Text] [Related]
9. [Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery]. Yang BG; Yu XP; Chen F; Lyu SZ; Li Q; He JQ; Yuan F Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jan; 45(1):19-25. PubMed ID: 28100341 [No Abstract] [Full Text] [Related]
10. A propensity score matched analysis to determine if second-generation drug-eluting stents outperform first-generation drug-eluting stents in a complex patient population. Loh JP; Pendyala LK; Kitabata H; Badr S; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R Int J Cardiol; 2013 Dec; 170(1):43-8. PubMed ID: 24169532 [TBL] [Abstract][Full Text] [Related]
11. First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: the Milan and New-Tokyo (MITO) registry. Naganuma T; Chieffo A; Takagi K; Panoulas VF; Mitomo S; Sticchi A; Latib A; Miyazaki T; Sato K; Costopoulos C; Fujino Y; Montorfano M; Carlino M; Nakamura S; Colombo A Catheter Cardiovasc Interv; 2015 Feb; 85(3):E63-9. PubMed ID: 25099758 [TBL] [Abstract][Full Text] [Related]
12. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648 [TBL] [Abstract][Full Text] [Related]
13. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. Ali MS; Groenwold RH; Belitser SV; Pestman WR; Hoes AW; Roes KC; Boer Ad; Klungel OH J Clin Epidemiol; 2015 Feb; 68(2):112-21. PubMed ID: 25433444 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Kirtane AJ; Gupta A; Iyengar S; Moses JW; Leon MB; Applegate R; Brodie B; Hannan E; Harjai K; Jensen LO; Park SJ; Perry R; Racz M; Saia F; Tu JV; Waksman R; Lansky AJ; Mehran R; Stone GW Circulation; 2009 Jun; 119(25):3198-206. PubMed ID: 19528338 [TBL] [Abstract][Full Text] [Related]
15. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Martens EP; de Boer A; Pestman WR; Belitser SV; Stricker BH; Klungel OH Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):1-8. PubMed ID: 17960554 [TBL] [Abstract][Full Text] [Related]
16. Examination of the treatment selection process in a multicenter observational study. Anstrom KJ; Brennan JM; Eisenstein EL; Federspiel JJ; Dai D; Peterson ED; Douglas PS Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):764-9. PubMed ID: 25116898 [TBL] [Abstract][Full Text] [Related]
17. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963 [TBL] [Abstract][Full Text] [Related]
18. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study. Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383 [TBL] [Abstract][Full Text] [Related]
19. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents. Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031 [TBL] [Abstract][Full Text] [Related]
20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]